Abstract
Neo-adjuvant chemotherapy (NAC) has become a standard treatment for advanced breast cancer because of the advantage of monitoring drug sensitivity and enabling breast-conserving therapy. The changes during NAC are also important to know the biological characteristics of the tumor. We experienced two cases with cystic degeneration and enhancement of the cyst wall during NAC for triple negative breast cancer (TNBC). They were diagnosed to have breast cancer with squamous metaplasia. In case 1, a 37-year-old woman with right breast cancer diagnosed as TNBC, T3N3M0, Stage 3b was treated with NAC. MRI showed a cystic degeneration with a diameter of 3.5 cm and enhancement of the cyst wall, and the other nodules were extinguished. The histopathological finding of the surgical specimen revealed solid tubular carcinoma with squamous metaplasia. In case 2, a 58-year-old woman with right breast cancer diagnosed as HER2 enriched subtype, T2N0M0 stage 2 was treated with NAC containing trastuzumab. The post-NAC MRI showed extinguishment of the mass in the right breast, but showed a cystic lesion with 24 mm in diameter and enhancement of its wall in the left breast. She underwent breast conserving surgery for bilateral breast cancer, and histopathological finding of the surgical specimen indicated complete remission of right breast cancer and squamous cell carcinoma developed in the left breast. These changes are impressive and remind us that there are metaplastic changes (especially for squamous metaplasia) with resistance to chemotherapy.
Similar content being viewed by others
References
Mieog JS, van der Hage JA, van de Velde CJ (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2:CD005002
Early Breast Cancer Trialists’ Collaborative Group (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27–39
Kumaki N, Umemura S, Tang X et al (2011) Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67. Breast Cancer 18:98–102
Fangberget A, Nilsen LB, Hole KH et al (2010) Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 21:1188–1199
Arlinghaus LR, Li X, Levy M et al (2010) Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J Oncol 2010:919620
Tavassoli FA (1992) Classification of metaplastic carcinomas of the breast. Pathol Annu 27(Pt 2):89–119
Pezzi CM, Patel-Parekh L, Cole K et al (2007) Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 14:166–173
Behranwala KA, Nasiri N, Abdullah N et al (2003) Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome. Eur J Surg Oncol 29:386–389
Zhu J, Li K, Dong X et al (2018) Metaplastic breast carcinoma composed of epithelial-myoepithelial carcinoma and squamous cell carcinoma: a case report. Medicine (Baltimore) 97:e0364
Goldberg MT, Llaneras J, Willson TD et al (2021) Squamous cell carcinoma arising in breast implant capsules. Ann Plast Surg 86:268–272
Rosen PP (1997) Squamous carcinoma. Rosen’s breast pathology, 2nd edn. Lippincott Williams Wilkins, Philadelphia, pp 455–461
Wong W, Brogi E, Reis-Filho JS et al (2021) Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ Breast Cancer 7:96
Vythianathan M, Fox P, Rhodes G et al (2019) Primary squamous carcinoma of breast—a rare entity: report of two cases and review of the literature. Pathology 51:529–531
Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750–2767
Abdelhafez AH, Musall BC, Adrada BE et al (2021) Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 185:1–12
Youk JH, Son EJ, Chung J et al (2012) Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes. Eur Radiol 22:1724–1734
Author information
Authors and Affiliations
Contributions
MI, HN, AY, and TO contributed to writing the manuscript.TO, YH, AY, TE, and HW, served as attending physicians of the present patients. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
Written informed consents were obtained from patients of cases 1 and 2 concerning the publication of their clinical and genomic information.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Inoue, M., Kimura, A., Oka, T. et al. Cystic degeneration during neo-adjuvant chemotherapy predicts squamous metaplasia of triple negative breast cancer: report of two cases. Int Canc Conf J 11, 247–252 (2022). https://doi.org/10.1007/s13691-022-00553-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-022-00553-y